We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01528007
First Posted: February 7, 2012
Last Update Posted: December 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hannu Alho, National Institute for Health and Welfare, Finland
  Purpose
The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.

Condition Intervention Phase
Pathological Gambling Drug: Naltrexone pharmacotherapy Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial

Resource links provided by NLM:


Further study details as provided by Hannu Alho, National Institute for Health and Welfare, Finland:

Primary Outcome Measures:
  • PG-YBOCS. [ Time Frame: Up to 21 weeks. ]
    The investigators will interview PG-YBOCS questionnaire from the participants.


Secondary Outcome Measures:
  • Alcohol use. [ Time Frame: Up to 21 weeks. ]
    The investigators will ask the participants to fill in AUDIT questionnaire.

  • Quality of life. [ Time Frame: Up to 21 weeks. ]
    The investigators will ask the participants to fill in RAND 36 questionnaire.


Enrollment: 100
Study Start Date: January 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo pill. Drug: Placebo
Placebo pill with no active ingredients.
Active Comparator: 50mg Naltrexone when needed Drug: Naltrexone pharmacotherapy
Naltrexone 50mg when graving to gamble.

Detailed Description:

All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation.

The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • pathological gambling (scores 5+ from SOGS-R and DSM-IV criteria)

Exclusion Criteria:

  • acute hepatitis
  • severe liver or kidney dysfunction
  • suicide risk or severe depression or other untreated mental health problem
  • participation to other gambling research at the same time
  • the use of drugs (especially opiates)
  • pregnancy
  • prisoners
  • retarded and mentally ill patients were also excluded
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01528007


Locations
Finland
National Institute for Health and Welfare
Helsinki, Uusimaa, Finland, 00530
Sponsors and Collaborators
National Institute for Health and Welfare, Finland
Investigators
Principal Investigator: Hannu Alho, Professor National Institute for Health and Welfare, Finland
Study Director: Tuuli Lahti, Adjunct Professor National Institute for Health and Welfare, Finland
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hannu Alho, Professor, National Institute for Health and Welfare, Finland
ClinicalTrials.gov Identifier: NCT01528007     History of Changes
Other Study ID Numbers: 03062010
2010-021123-26 ( EudraCT Number )
First Submitted: October 28, 2011
First Posted: February 7, 2012
Last Update Posted: December 5, 2013
Last Verified: December 2013

Keywords provided by Hannu Alho, National Institute for Health and Welfare, Finland:
Pathological gambling
Treatment intervention

Additional relevant MeSH terms:
Gambling
Disruptive, Impulse Control, and Conduct Disorders
Mental Disorders
Naltrexone
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents